The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis

IF 13.4 Q1 GERIATRICS & GERONTOLOGY

Lancet Healthy Longevity Pub Date : 2025-02-01 DOI:10.1016/j.lanhl.2024.100679

Durga Kulkarni MPH , Bingbing Cong MMed , Mamata Jyothish Kumar Ranjini MPH , Geetika Balchandani IBDP , Shuting Chen BSMed , Jingyi Liang MSc , Lina González Gordon PhD , Ajoke Sobanjo-ter Meulen MD , Xin Wang PhD , Prof You Li PhD , Richard Osei-Yeboah PhD , Kate Templeton PhD , Prof Harish Nair PhD

{"title":"The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis","authors":"Durga Kulkarni MPH , Bingbing Cong MMed , Mamata Jyothish Kumar Ranjini MPH , Geetika Balchandani IBDP , Shuting Chen BSMed , Jingyi Liang MSc , Lina González Gordon PhD , Ajoke Sobanjo-ter Meulen MD , Xin Wang PhD , Prof You Li PhD , Richard Osei-Yeboah PhD , Kate Templeton PhD , Prof Harish Nair PhD","doi":"10.1016/j.lanhl.2024.100679","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The human metapneumovirus (hMPV)-associated disease burden in older adults remains under-researched. We aimed to systematically estimate the global burden of hMPV-associated disease in older adults.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, Global Health, CINAHL, Web of Science, and Global Index Medicus in February, 2023, November, 2023, and October, 2024; and CNKI, Wanfang, and CQVip, in April, 2024, and October, 2024. We included studies conducted over at least 12 consecutive months, reporting on adults aged 60 years or older, and with laboratory-confirmed hMPV infections. Critical appraisal of included studies was conducted using the Joanna Briggs Institute critical appraisal tools. To estimate the hMPV pooled proportions positive in acute respiratory infections (ARIs), random effects meta-analyses were conducted. Using Monte Carlo simulation, we estimated the hMPV-associated hospitalisations globally and separately in high-income countries, low-income and middle-income countries, and the USA in individuals aged 65 years or older in 2019, as most studies reported on this age group. The hMPV-associated ARI incidence in countries other than the USA and in outpatient or community settings in the USA was summarised narratively due to scarcity of data. The review protocol was registered on PROSPERO (CRD42023422325).</div></div><div><h3>Findings</h3><div>46 studies conducted between 2005 and 2023, and reporting on hMPV proportion positive estimates (n=36, with 29 866 laboratory tests), hospitalisation rates in the USA (n=4), and hMPV incidence (n=6) were included. We estimated 473 000 (95% CI 396 000–777 000) hMPV-associated hospitalisations globally, of which 185 000 (105 000–340 000) were in high-income countries (n=6 studies), and 288 000 (193 000–436 000) in low-income and middle-income countries (n=10 studies) in people aged 65 years or older in 2019. In the USA, the pooled hMPV-associated hospitalisation rate was 231 (95% CI 41–421) per 100 000 people in adults aged 65 years or older, representing approximately 122 000 (41 000–398 000) hospital admissions in this population in 2019.</div></div><div><h3>Interpretation</h3><div>hMPV-associated ARIs contribute to a substantial disease and hospitalisation burden in older adults. However, more large-scale surveillance studies and greater investment in research and diagnostic methods are required to develop reliable estimates.</div></div><div><h3>Funding</h3><div>Icosavax, a member of the AstraZeneca group.</div></div>","PeriodicalId":34394,"journal":{"name":"Lancet Healthy Longevity","volume":"6 2","pages":"Article 100679"},"PeriodicalIF":13.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Healthy Longevity","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666756824002058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The human metapneumovirus (hMPV)-associated disease burden in older adults remains under-researched. We aimed to systematically estimate the global burden of hMPV-associated disease in older adults.

Methods

We searched MEDLINE, Embase, Global Health, CINAHL, Web of Science, and Global Index Medicus in February, 2023, November, 2023, and October, 2024; and CNKI, Wanfang, and CQVip, in April, 2024, and October, 2024. We included studies conducted over at least 12 consecutive months, reporting on adults aged 60 years or older, and with laboratory-confirmed hMPV infections. Critical appraisal of included studies was conducted using the Joanna Briggs Institute critical appraisal tools. To estimate the hMPV pooled proportions positive in acute respiratory infections (ARIs), random effects meta-analyses were conducted. Using Monte Carlo simulation, we estimated the hMPV-associated hospitalisations globally and separately in high-income countries, low-income and middle-income countries, and the USA in individuals aged 65 years or older in 2019, as most studies reported on this age group. The hMPV-associated ARI incidence in countries other than the USA and in outpatient or community settings in the USA was summarised narratively due to scarcity of data. The review protocol was registered on PROSPERO (CRD42023422325).

Findings

46 studies conducted between 2005 and 2023, and reporting on hMPV proportion positive estimates (n=36, with 29 866 laboratory tests), hospitalisation rates in the USA (n=4), and hMPV incidence (n=6) were included. We estimated 473 000 (95% CI 396 000–777 000) hMPV-associated hospitalisations globally, of which 185 000 (105 000–340 000) were in high-income countries (n=6 studies), and 288 000 (193 000–436 000) in low-income and middle-income countries (n=10 studies) in people aged 65 years or older in 2019. In the USA, the pooled hMPV-associated hospitalisation rate was 231 (95% CI 41–421) per 100 000 people in adults aged 65 years or older, representing approximately 122 000 (41 000–398 000) hospital admissions in this population in 2019.

Interpretation

hMPV-associated ARIs contribute to a substantial disease and hospitalisation burden in older adults. However, more large-scale surveillance studies and greater investment in research and diagnostic methods are required to develop reliable estimates.

Funding

Icosavax, a member of the AstraZeneca group.

查看原文本刊更多论文

与人类偏肺病毒相关的老年人急性呼吸道感染的全球负担：系统回顾和荟萃分析。

背景：老年人人偏肺病毒（hMPV）相关疾病负担的研究尚不充分。我们的目的是系统地估计老年人hmpv相关疾病的全球负担。方法：检索2023年2月、2023年11月和2024年10月的MEDLINE、Embase、Global Health、CINAHL、Web of Science和Global Index Medicus；2024年4月、2024年10月、CNKI、万方、CQVip。我们纳入了至少连续12个月进行的研究，报告了60岁或以上的成年人，并且实验室证实了hMPV感染。使用乔安娜布里格斯研究所的批判性评估工具对纳入的研究进行批判性评估。为了估计急性呼吸道感染（ARIs）中hMPV阳性的合并比例，进行了随机效应荟萃分析。使用蒙特卡罗模拟，我们估计了2019年全球和高收入国家、低收入和中等收入国家以及美国65岁及以上人群中与hmpv相关的住院人数，正如大多数研究报告的那样。由于缺乏数据，在美国以外的国家和美国门诊或社区环境中，hmpv相关的ARI发病率进行了叙述性总结。审查方案在PROSPERO上注册（CRD42023422325）。研究结果：在2005年至2023年期间进行了46项研究，报告了hMPV阳性估计比例（n=36，进行了29866次实验室检查）、美国的住院率（n=4）和hMPV发病率（n=6）。我们估计2019年全球有47.3万例（95% CI 39.6 - 77.7万）hmpv相关住院，其中18.5万例（10.5万-34万）发生在高收入国家（n=6项研究），28.8万例（19.3万- 43.6万）发生在低收入和中等收入国家（n=10项研究），患者年龄在65岁或以上。在美国，65岁及以上成年人中，与hmpv相关的总住院率为每10万人中231人（95% CI 41-421）， 2019年该人群中住院人数约为12.2万（4.1万- 39.8万）。解释：hmpv相关的ARIs是老年人的主要疾病和住院负担。然而，需要更多的大规模监测研究和对研究和诊断方法的更多投资，以制定可靠的估计。资助：Icosavax，阿斯利康集团的成员。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Healthy Longevity GERIATRICS & GERONTOLOGY-

CiteScore

16.30

自引率

2.30%

发文量

192

审稿时长

12 weeks

期刊介绍： The Lancet Healthy Longevity, a gold open-access journal, focuses on clinically-relevant longevity and healthy aging research. It covers early-stage clinical research on aging mechanisms, epidemiological studies, and societal research on changing populations. The journal includes clinical trials across disciplines, particularly in gerontology and age-specific clinical guidelines. In line with the Lancet family tradition, it advocates for the rights of all to healthy lives, emphasizing original research likely to impact clinical practice or thinking. Clinical and policy reviews also contribute to shaping the discourse in this rapidly growing discipline.